• AKULA NIKHIL PRASHANT
• SANDEEP REDDY CHERUKU
• D. SREEKANTH
• S.V.S. RAHUL

The ocular drug delivery passes through a number of anatomical physiological and ocular barriers, which have been a bottleneck for the ophthalmologists. The ocular barriers decrease the absorption of the therapeutic agents. Transportation of drugs followed by traditional dosage forms is restricted to the eye, and therapeutic drug concentrations in the target tissues are not maintained for a long duration since the eyes are protected by a unique anatomy and physiology. For the treatment of the anterior segment of the eye, various droppable products to prolong the retention time on the ocular surface have been introduced in the market. On the other hand, direct intravitreal implants, using biodegradable or non-biodegradable polymer technology, have been widely investigated for the treatment of chronic vitreoretinal diseases. There is urgent need to develop ocular drug delivery systems which provide controlled release for the treatment of chronic diseases, and increase patient’s and doctor’s convenience to reduce the dosing frequency and invasive treatment. In this article, review of the study is to highlight the newer developments in the pharmaceutical ophthalmic formulations, such as formulation of in situ gels, nanoparticles, liposomes, nano-suspension, micro-emulsion, ocular inserts and so on, and their progress to overcome the problems associated with the existing conventional dosage forms and also to improve the bioavailability as well as the sustained release of the drug at the target location

The ocular drug delivery passes through a number of anatomical physiological and ocular barriers, which have been a bottleneck for the ophthalmologists. The ocular barriers decrease the absorption of the therapeutic agents. Transportation of drugs followed by traditional dosage forms is restricted to the eye, and therapeutic drug concentrations in the target tissues are not maintained for a long duration since the eyes are protected by a unique anatomy and physiology. For the treatment of the anterior segment of the eye, various droppable products to prolong the retention time on the ocular surface have been introduced in the market. On the other hand, direct intravitreal implants, using biodegradable or non-biodegradable polymer technology, have been widely investigated for the treatment of chronic vitreoretinal diseases. There is urgent need to develop ocular drug delivery systems which provide controlled release for the treatment of chronic diseases, and increase patient’s and doctor’s convenience to reduce the dosing frequency and invasive treatment. In this article, review of the study is to highlight the newer developments in the pharmaceutical ophthalmic formulations, such as formulation of in situ gels, nanoparticles, liposomes, nano-suspension, micro-emulsion, ocular inserts and so on, and their progress to overcome the problems associated with the existing conventional dosage forms and also to improve the bioavailability as well as the sustained release of the drug at the target location

" PROGRESSIVE STUDIES IN OCULAR DRUG DELIVERY", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 6, page no.c88-c97, June-2022, Available :http://www.jetir.org/papers/JETIR2206210.pdf

" PROGRESSIVE STUDIES IN OCULAR DRUG DELIVERY", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 6, page no. ppc88-c97, June-2022, Available at : http://www.jetir.org/papers/JETIR2206210.pdf